The cyclo-oxygenase-2 inhibitor, rofecoxib, attenuates mucosal damage due to colitis induced by trinitrobenzene sulphonic acid in rats

European Journal of Pharmacology

Volumn 481, Issue 2-3, 2003, Pages 281-291

  Martín, Antonio Ramón ^a   Villegas, Isabel ^a   La Casa, Carmen ^a   De La Lastra, Catalina Alarcón ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Apoptosis; Colitis; Cyclo oxygenase 2; Interleukin 1 ; Neutrophil; Prostaglandin; TNBS (trinitrobenzene sulphonic acid)

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INTERLEUKIN 1BETA; MYELOPEROXIDASE; PROSTAGLANDIN D2; PROSTAGLANDIN E2; ROFECOXIB; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; COLITIS; COLON; COLON MUCOSA; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG MECHANISM; EDEMA; ENZYME ACTIVITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; INTESTINE CELL; INTESTINE NECROSIS; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; THICKNESS;

EID: 0344826835     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.09.033     Document Type: Article

References (44)

1. Agoff S.N., Brentnall T.A., Crispin D.A., Taylor S.L., Raaka S., Haggitt R.C., Reed M.W., Afonina I.A., Rabinovitch P.S., Stevens A.C., Feng Z., Bronner M.P. The role of cyclo-oxygenase 2 in ulcerative colitis-associated neoplasia. Am. J. Pathol. 157:2000;737-745.
2. Ajuebor M.N., Singh A., Wallace J.L. Cyclooxygenase-2-derived prostaglandin D2 is an early anti-inflammatory signal in experimental colitis. Am. J. Physiol. 279:2000;G238-G244.
3. Alarcón de la Lastra C., Martín M.J., Motilva V. Antiulcer and gastroprotective effect of quercetin: a gross and histologic study. Pharmacology. 48:1994;56-62.
4. Arico S., Pattingre S., Bauvy C., Gane P., Barbat A., Codogno P., Ogier-Denis E. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide- dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J. Biol. Chem. 277:2002;27613-27621.
5. Bobin-Dubigeon C., Collin X., Grimaud N., Robert J.M., Le Baut G., Petit J.Y. Effects of tumor necrosis factor-α synthesis inhibitors on rat trinitrobenzene sulphonic acid-induced chronic colitis. Eur. J. Pharmacol. 431:2001;103-110.
6. Bonner G.F. Using COX-2 inhibitors in IBD: anti-inflammatories inflame a controversy. Am. J. Gastroenterol. 97:2002;783-785.
7. Bonner G.F., Walczak M., Kitchen L., Bayona M. Tolerance of nonsteroidal anti-inflammatory drugs in patients with inflammatory bowel disease. Am. J. Gastroenterol. 95:2000;1055-1058.
8. Campbell N.B., Jones S.L., Blikslager A.T. The effects of cyclo-oxygenase inhibitors on bile-injured and normal equine colon. Equine Vet. J. 34:2002;493-498.
9. Carty E., De Brabander M., Feakins R.M., Rampton D.S. Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper. Gut. 46:2000;487-492.
10. Castagliuolo I., Lamont J.T., Qiu B., Fleming S.M., Bhaskar K.R., Nikulasson S.T., Kornetsky C., Pothoulakis C. Acute stress causes mucin release from rat colon: role of corticotropin releasing factor and mast cells. Am. J. Physiol. 271:1996;G884-G892.
11. Cuzzocrea S., Mazzon E., Serraino I., Dugo L., Centorrino T., Ciccolo A., Sautebin L., Caputi A.P. Celecoxib, a selective cyclo-oxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulphonic acid in rats. Eur. J. Pharmacol. 431:2001;91-102.
12. Dannhart G., Kiefer W. Cyclooxygenase inhibitors - current status and future prospects. Eur. J. Med. Chem. 36:2001;109-126.
13. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 115:1998;182-205.
14. Grisham M.B., Beniot J.N., Granger D.N. Assessment of leucocyte in involvement during ischemia and reperfusion on the intestine. Packer L., Glazer A.E. Methods in Enzymology. Oxygen Radicals in Biological Systems. 1990;729-741 Academic Press, San Diego.
15. Guo X., Wang W.P., Ko J.K., Cho C.H. Involvement of neutrophils and free radicals in the potentiating effects of passive cigarette smoking on inflammatory bowel disease in rats. Gastroenterology. 117:1999;884-892.
16. Guo X., Liu E.S., Ko J.K., Wong B.C., Ye Y., Lam S., Cho C. Protective role of cyclooxygenase inhibitors in the adverse action of passive cigarette smoking on the initiation of experimental colitis in rats. Eur. J. Pharmacol. 411:2001;193-203.
17. Gupta R.A., Dubois N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. 1:2001;11-21.
18. Hara A., Yoshimi N., Niwa M., Ino N., Mori H. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer lines. Jpn. J. Cancer Res. 88:1997;600-604.
19. Iwamoto M., Koji T., Makiyama K., Kobayashi N., Nakane P.K. Apoptosis of crypt epithelial cells in ulcerative colitis. J. Pathol. 180(2):1996;152-159.
20. Kankuri E., Vaali K., Korpela R., Paakkari I., Vapaatalo H., Moilanen E. Effects of a COX-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut. Inflammation. 25:2001;301-309.
21. Karmeli F., Cohen P., Rachmilewitz D. Cyclo-oxygenase-2 inhibitors ameliorate the severity of experimental colitis in rats. Eur. J. Gastroenterol. Hepatol. 12:2000;223-231.
22. Khan I., Al-Awadi F.M., Thomas N., Haridas S., Anim J.M. Cyclo-oxygenase-2 inhibition and experimental colitis: beneficial effects of phosphorothioated antisense oligonucleotide and meloxicam. Scand. J. Gastroenterol. 37:2002;1428-1436.
23. Kruidenier L., Verspaget H.W. Oxidative stress as a pathogenic factor in inflammatory bowel disease - radicals or ridiculous? Aliment. Pharmacol. Ther. 16:2002;1997-2015.
24. Kusunoki N., Yamazaki R., Kawai S. Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors. Arthritis Rheum. 46:2002;3159-3167.
25. Lesch C.A., Kraus E.R., Sanchez B., Gilbertsen R., Guglietta A. Lack of beneficial effect of COX-2 inhibitors in an experimental model of colitis. Methods Find Exp. Clin. Pharmacol. 21:1999;99-104.
26. Mahadevan U., Loftus E.V., Tremaine W.J., Sandborn W.J. Safety of cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am. J. Gastroenterol. 97:2002;910-914.
27. Morris G.P., Beck P.L., Herridge M.S., Depew W.T., Szewczuk M.R., Wallace J.L. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 96(3):1989;795-803.
28. Newberry R.D., Stenson W.F., Lorenz R.G. Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen. Nat. Med. 5:1999;900-906.
29. Nitta M., Hirata I., Toshina K., Murano M., Maemura K., Hamamoto N., Sasaki S., Yamauchi H., Katsu K. Expression of the EP4 prostaglandin E2 receptor subtype with rat dextran sodium sulphate colitis: colitis suppression by a selective agonist, ONO-AE1-329. Scand. J. Immunol. 56:2002;66-75.
30. Phillips T.E., Stanley C.M., Wilson J. The effect of 16,16-dimethyl prostaglandin E2 on proliferation of an intestinal goblet cell line and its synthesis and secretion of mucin glycoproteins. Prostaglandins Leukot. Essent. Fat. Acids. 48:1993;423-428.
31. Qadri S.S., Wang J.H., Redmond K.C., O' Donnell A.F., Aherne T., Redmond H.P. The role of COX-2 inhibitors in lung cancer. Ann. Thorac. Surg. 74:2002;1648-1652.
32. Reuter B.K., Asfaha S., Buret A., Sharkey K.A., Wallace J.L. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J. Clin. Invest. 98:1996;2076-2085.
33. Rogler G., Andus T. Cytokines in inflammatory bowel disease. World J. Surg. 22(4):1998;382-389.
34. Sartor R.B. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology. 106:1994;533-539.
35. Siegmund B. Interleukin-1beta converting enzyme (caspase-1) in intestinal inflammation. Biochem. Pharmacol. 64:2002;1-8.
36. Simon L.S. Biology and toxic effects of nonsteroidal anti-inflammatory drugs. Curr. Opin. Rheumatol. 10:1998;153-158.
37. Singer I.I., Kawka D.W., Schloemann S.et al. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology. 115:1998;297-306.
38. Tardieu D., Jaeg J.P., Deloly A., Corpet D.E., Cadet J., Petit C.R. The COX-2 inhibitor nimesulide suppresses superoxide and 8-hydroxy-deoxyguanosine formation, and stimulates apoptosis in mucosa during early colonic inflammation in rats. Carcinogenesis. 21:2000;973-976.
39. Torres M.I., García-Martín M., Fernández M.I., Nieto N., Gil A., Ríos A. Experimental colitis induced by trinitrobenzenesulphonic acid. An ultrastructural and histochemical study. Dig. Dis. Sci. 44:1999;2523-2529.
40. Vane J.R., Botting R.M. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am. J. Med. 104:1998;2S-8S.
41. Villegas I., La Casa C., Orjales A., Alarcón de la Lastra C. Effects of dosmalfate, a new cytoprotective agent, on acute and chronic trinitrobenzene sulphonic acid-induced colitis in rats. Eur. J. Pharmacol. 460:2003;209-218.
42. Warner T.D., Giuliano F., Vojnovic I., Bukada A., Mitchell J.A., Vane J.R. Non-steroidal drug selectivities for cyclooxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl. Acad. Sci. U. S. A. 96(13):1999;7563-7568. (Find. Exp. Clin. Pharmacol. 21, 99-104.).
43. Yamazaki R., Kusunoki N., Matsuzaki T., Hashimoto S., Kawai S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett. 531:2002;278-284.
44. Yue G., Lai P.S., Yin K., Sun F.F., Nagele R.G., Liu X., Linask K.K., Wang C., Lin K.T., Wong P.Y. Colon epithelial cell death in 2,4,6- trinitrobenzenesulfonic acid-induced colitis is associated with increased inducible nitric-oxide synthase expression and peroxynitrite production. J. Pharmacol. Exp. Ther. 297(3):2001;915-925.